Study #2024-0054
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Blinatumomab, Asciminib
Description
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Study phase:
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.